NICE reaches a deal with Roche on access to oral SMA drug Ev...

Roche's oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with

NICE 'no' to Roche's risdiplam for SMA not unexpected, says ...

NICE has rejected routine NHS funding for Roche's Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn't come as a surprise to patient association

Novartis pulls rival to Roche’s risdiplam in SMA, says marke...

FDA cues up May verdict for Roche’s SMA challenger risdiplam